To examine antihypertensive effect and safety of administration of CS-3150 in patients with severe hypertension (Grade III).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
CS-3150 2.5 to 5mg, orally, once daily after breakfast
Unnamed facility
Sapporo, Japan
Change from baseline in sitting systolic and diastolic blood pressure
Time frame: Baseline to end of Week 8
Time course of systolic and diastolic blood pressure
Time frame: Baseline to end of Week 8
Proportion of patients achieving blood pressure control
Time frame: Baseline to end of Week 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.